{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is ABVC BioPharma, Inc. overvalued or undervalued?
As of August 14, 2023, ABVC BioPharma, Inc. is considered overvalued with significant financial concerns, reflected in its high Price to Book Value of 4.85 and negative ratios, despite a strong year-to-date stock performance of 232.20%.
Is ABVC BioPharma, Inc. technically bullish or bearish?
As of April 21, 2025, ABVC BioPharma, Inc. shows a strong bullish trend supported by positive indicators across multiple time frames, including bullish MACD, Bollinger Bands, and moving averages, despite a neutral RSI.
What does ABVC BioPharma, Inc. do?
ABVC BioPharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $1 million and a market cap of $34.02 million. Key metrics include a debt-to-equity ratio of 0.37 and a return on equity of -41.12%.
How big is ABVC BioPharma, Inc.?
As of Jun 18, ABVC BioPharma, Inc. has a market capitalization of 34.02 million, with net sales of 0.51 million and a net profit of -2.21 million over the last four quarters. The company reported shareholder's funds of 1.23 million and total assets of 7.54 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
